<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361528</url>
  </required_header>
  <id_info>
    <org_study_id>2014.856</org_study_id>
    <nct_id>NCT02361528</nct_id>
  </id_info>
  <brief_title>GM-CSF to Decrease ICU Acquired Infections</brief_title>
  <acronym>GRID</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-controlled Multicenter Trial of GRanulocyte-Macrophage Colony-stimulating Factor Administration to Decrease ICU Acquired Infections in Sepsis-induced ImmunoDepression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concept of acquired immunodeficiency after a first severe infection in the ICU is widely
      described in the literature. There is a dual risk: increased mortality and increased
      secondary infections. Several approaches of immunostimulatory treatments have been proposed
      in the literature. The treatment proposed by this study consists of the administration of
      Granulocyte-macrophage colony-stimulating factor (GM-CSF), colony stimulating factor widely
      used particularly in the USA where it is marketed. A phase 2 clinical trial was conducted in
      Germany in 2009.

      The main objective is to measure the incidence of ICU-acquired infections in 2 groups of
      patients treated by GM-CSF or placebo. ICU patients at risk are defined as surviving at D3
      from a severe sepsis or septic shock and presenting a sepsis associated immunodepression. The
      detection of immunosuppressed patients will be achieved by measuring the HLA-DR (Human
      Leucocyte Antigen DR)with a threshold of less to 8000 sites.

      Our hypothesis is that the number of secondary infections (primary endpoint) will be
      significantly reduced in the treated group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2015</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients presenting at least one ICU-acquired infection at D28 or ICU discharge.</measure>
    <time_frame>At Day 28 or ICU discharge.</time_frame>
    <description>ICU-acquired infections will be recorded in accordance with the definitions of the European CDC used in the French network of IAI surveillance Rea Raisin. An independent committee blinded to treatment group will ensure the classification of hospital-acquired infections.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and incidence density of pneumonia, catheter related infections, and urinary tract infections</measure>
    <time_frame>At Day 28 or ICU discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at D28, end of ICU and hospital stay, and at 1 year</measure>
    <time_frame>At Day 28 or ICU discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days</measure>
    <time_frame>At Day 28 or ICU discharge.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events and number of patients having presented at least one serious adverse event.</measure>
    <time_frame>At Day 28 or ICU discharge.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Septic Shock</condition>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>Leukine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, once per day during 5 days by subcutaneous route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim: Leukine (Genzyme USA)</intervention_name>
    <description>Leukine: 125 µg/m² daily, subcutaneously, for 5 days.</description>
    <arm_group_label>Leukine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo subcutaneously, for 5 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ICU patients presenting a severe sepsis or a septic shock associated with a sepsis-induced
        immunosuppression.

          1. - Severe sepsis OR septic shock defined by the association of: at least 2 criteria of
             Systemic Inflammation Response Syndrome (SIRS) a clinically or microbiologically
             defined infection and respectively at least one organ failure (level ≥ 2 in one organ
             failure of the SOFA score) OR the need of a vasopressor treatment (epinephrine or
             norepinephrine ≥ 0,25mg/kg/min for at least 6 hrs to maintain a systolic pressure ≥ 90
             mmHg or a mean arterial pressure ≥ 65 mmHg).

          2. - AND Sepsis-induced immunosuppression: reduced mHLA-DR levels (&lt; 8,000 monoclonal
             antibodies (mAb) per cell at D3).

        Exclusion Criteria:

          1. - Therapeutic limitation

          2. Evolutive hemopathy, neutropenia &lt; 500/mm3, stemcell transplant

          3. Solid tumor with on-going chemotherapy or radiotherapy

          4. Human immunodeficiency virus (HIV) infection with CD 4 count &lt; 200 cell/mm3

          5. Immunosuppressive treatment (including corticosteroid at immunosuppressive dose : &gt; 10
             mg equivalent prednisolone and cumulative dose &gt; 700 mg)

          6. Primary immunodeficiency .

          7. Extra corporeal circulation within one month

          8. Recent cardio-pulmonary resuscitation (within the current clinical episode)

          9. Patients admitted in ICU for extensive burns

         10. Contraindications to sargramostim

         11. Pregnant or lactating women

         12. Participation to another interventional study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens Hopital SUD</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing 1 place Lucie et Raymond Aubrac</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel MONTPIED</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble- Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble-Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTMC CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Severe sepsis</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Hospital-acquired infections</keyword>
  <keyword>ICU-acquired infections</keyword>
  <keyword>HLA-DR</keyword>
  <keyword>Monocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

